Drugs / Autologous CIK
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04802070 | Jan 2021 → Mar 2023 | sarcoma | Prof. Franca Fagioli | Completed | No outcome recorded |
| Phase 1 | NCT03782363 | Dec 2020 → Apr 2023 | sarcoma | Italian Sarcoma Group | Withdrawn | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous CIK | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03782363 ↗ |
| Modality | Cell therapy | “autologous ex-vivo CIK cell expanded” NCT04802070 ↗ |